Conversely, in hepatoblastoma, WNT pathway dysregulation often arises from mutations in CTNNB1 [7] as well as deletions or the epigenetic silencing of AXIN1 and AXIN2 [53], which act as negative regulators of the pathway. This evidence concerns the gene AXIN2 and hepatoblastoma.